{"id":"allert","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions"},{"rate":null,"effect":"Mild systemic allergic reactions"},{"rate":null,"effect":"Itching or swelling at injection site"}]},"_chembl":null,"_dailymed":{"setId":"3cc17fc6-d143-47af-be65-86301873a522","title":"ALLERTNESS AID (CAFFEINE) TABLET [SELECT CORPORATION]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AllerT uses synthetic peptides derived from major allergen epitopes to induce immune tolerance and reduce allergic responses. The therapy works by shifting the immune response away from IgE-mediated reactions toward regulatory T cell activation and IgG-blocking antibody production, thereby desensitizing patients to their specific allergens.","oneSentence":"AllerT is an allergen immunotherapy that modulates immune tolerance to specific allergens through a peptide-based approach.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:21:12.955Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis and asthma (grass pollen allergy)"}]},"trialDetails":[{"nctId":"NCT02943720","phase":"PHASE2","title":"ATIBAR - Efficacy and Safety of Two Doses of AllerT in Patients Allergic to Birch Pollen","status":"COMPLETED","sponsor":"Anergis","startDate":"2016-09","conditions":"Allergic Rhinitis","enrollment":421},{"nctId":"NCT02271009","phase":"PHASE2","title":"Compare Dose Regimens of AllerT, in Adults With Allergic Rhino-Conjunctivitis to Birch Pollen Studied in EEC","status":"COMPLETED","sponsor":"Anergis","startDate":"2014-10","conditions":"Allergic Rhino-Conjunctivitis","enrollment":213},{"nctId":"NCT02143583","phase":"","title":"Follow-up of Study AN004T to Assess the Persistence of AllerT Efficacy During the 2nd to 4th Season After Treatment","status":"COMPLETED","sponsor":"Anergis","startDate":"2014-02","conditions":"Birch Pollen Allergy","enrollment":196},{"nctId":"NCT01720251","phase":"PHASE2","title":"Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy","status":"COMPLETED","sponsor":"Anergis","startDate":"2012-10","conditions":"Allergic Rhinitis, Rhinoconjunctivitis","enrollment":240},{"nctId":"NCT01728519","phase":"PHASE1, PHASE2","title":"Phase I/IIa Clinical Evaluation of AllerT vs Placebo in Subjects Allergic to Birch Pollen","status":"TERMINATED","sponsor":"Anergis","startDate":"2008-08","conditions":"Allergic Rhinitis, Allergy","enrollment":29},{"nctId":"NCT01719133","phase":"PHASE1","title":"Skin Prick Tests With AllerT in Subjects Allergic to Birch Pollen","status":"COMPLETED","sponsor":"Anergis","startDate":"2008-02","conditions":"Allergic Rhinitis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Continuous overlapping peptides"],"phase":"marketed","status":"active","brandName":"AllerT","genericName":"AllerT","companyName":"Anergis","companyId":"anergis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AllerT is an allergen immunotherapy that modulates immune tolerance to specific allergens through a peptide-based approach. Used for Allergic rhinitis and asthma (grass pollen allergy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}